Recombinant Mouse CD229/SLAMF3 Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 2555-CD
Key Product Details
Product Specifications
Source
Mouse myeloma cell line, NS0-derived mouse CD229/SLAMF3 protein
Lys48-Phe454, with a C-terminal 6-His tag
Lys48-Phe454, with a C-terminal 6-His tag
Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Lys48
Predicted Molecular Mass
46 kDa
SDS-PAGE
60-80 kDa, reducing conditions
Activity
Measured by its ability to enhance anti-CD3-induced proliferation of mouse CD3+ T cells.
The ED50 for this effect is 0.5-2.5 μg/mL.
The ED50 for this effect is 0.5-2.5 μg/mL.
Formulation, Preparation and Storage
2555-CD
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution |
Reconstitute at 100 μg/mL in PBS.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: CD229/SLAMF3
References
- Bhat, R. et al. (2006) J. Leukoc. Biol. 79:417.
- de la Fuente, M.A. et al. (2001) Blood 97:3513.
- Sandrin, M.S. et al. (1992) J. Immunol. 149:1636.
- Romero, X. et al. (2004) Tissue Antigens 64:132.
- Hogarth, P.M. et al. (1980) Immunogenetics 11:65.
- Mathieson, B.J. et al. (1980) J. Immunol. 125:2127.
- Sintes, J. et al. (2007) Tissue Antigens 70:355.
- Romero, X. et al. (2005) J. Immunol. 174:7033.
- Del Valle, J.M. et al. (2003) J. Biol. Chem. 278:17430.
- Martin, M. et al. (2005) J. Immunol. 174:5977.
- Sayos, J. et al. (2001) Blood 97:3867.
- Graham, D.B. et al. (2006) J. Immunol. 176:291.
Long Name
SLAM Family Member 3
Alternate Names
CD229, Ly9, SLAMF3
Gene Symbol
LY9
UniProt
Additional CD229/SLAMF3 Products
Product Documents for Recombinant Mouse CD229/SLAMF3 Protein, CF
Product Specific Notices for Recombinant Mouse CD229/SLAMF3 Protein, CF
For research use only
Loading...
Loading...
Loading...